A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19

• Research type

  Research Study

• Full title

  A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19

• IRAS ID

  1007159

• Contact name

  Jack Churchill

• Contact email

  UKCWOW@iqvia.com

• Sponsor organisation

  Atea Pharmaceuticals, Inc.

• Eudract number

  2022-003268-25

• Clinicaltrials.gov Identifier

  NCT05629962

• Research summary

  A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  23/NE/0041

• Date of REC Opinion

  30 Aug 2023

• REC opinion

  Further Information Favourable Opinion